ADAR and cancer: For ADAR, patients with low expression demonstrated enrichment of several cancer-related pathways, including interferon-γ response (p = 0.009, FDR = 0.091), mTORC1 signaling (p = 0.011, FDR = 0.204), and IL-2/STAT5 signaling (p = 0.018, FDR = 0.127), together with downregulation of KRAS signaling (p = 0.047, FDR = 0.200) (Figure 11).